Financials

  • Market Capitalization 37.47 M
  • Employee 28
  • Founded 1996
  • CEO N/A
  • Website www.plustherapeutics.com
  • Headquarter Delaware, United States
  • FIGI BBG000C1Z086
  • Industry Technology
総売上高
当期純利益
1株当たり基本利益(基本EPS)
有利子負債合計
フリーキャッシュフロー
現金および現金同等物
株価収益率
-1.77
売上高対価格比率
7.65

PLUS THERAPEUTICS Inc

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Plus Therapeutics also commercialized a molecular diagnostic service, CNSide®.

ニュース